ホーム › 前立腺がん › ユタ › Salt Lake City
Salt Lake City、UTにおける前立腺がんの臨床試験
Salt Lake Cityとその周辺地域（約30マイル以内）の拠点で、前立腺がんに関する15件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Study of AR Suppression With Carotuximab in Metastatic, Castration-Resistant Prostate Canc
被験者募集中第2相
- Huntsman Cancer Institute and Hospital, Salt Lake City
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
被験者募集中第1相
- University of Utah - Huntsman Cancer Institute, Salt Lake City
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
被験者募集中第3相
- LDS Hospital, Salt Lake City
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
被験者募集中第3相
- Huntsman Cancer Institute, Salt Lake City
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
被験者募集中第3相
- University of Utah Sugarhouse Health Center, Salt Lake City
- Huntsman Cancer Institute/University of Utah, Salt Lake City
- LDS Hospital, Salt Lake City
- 他1件
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
被験者募集中第3相
- Research Site, Salt Lake City
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
被験者募集中第3相
- Huntsman Cancer Institute/University of Utah, Salt Lake City
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
被験者募集中第1相
- Huntsman Cancer Institute, University of Utah, Salt Lake City
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer
被験者募集中第2相
- Huntsman Cancer Institute/University of Utah, Salt Lake City
Creatine Supplementation and Resistance Training to Preserve Muscle Mass and Attenuate Cancer Progression
被験者募集中第3相
- Huntsman Cancer Institute, Salt Lake City
Multimodal Telerehabilitation of Rural Patients With Advanced Prostate Cancer
被験者募集中
- Huntsman Cancer Institute at University of Utah, Salt Lake City
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
被験者募集中第1/2相
- START Center for Cancer Care - Mountain Region, Salt Lake City
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Salt Lake City
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
被験者募集中第3相
- University of Utah Sugarhouse Health Center, Salt Lake City
- Huntsman Cancer Institute/University of Utah, Salt Lake City
- George E Wahlen Department of Veterans Affairs Medical Center, Salt Lake City
Impact of Multimodal Telerehabilitation in Rural Patients With Metastatic Prostate Cancer
被験者募集中
- University of Utah Huntsman Cancer Institute, Salt Lake City
他の都市における前立腺がんの試験
- New York City, NY103件の研究
- Houston, TX76件の研究
- Los Angeles, CA61件の研究
- Boston, MA59件の研究
- St. Louis, MO46件の研究
- Chicago, IL45件の研究
- San Francisco, CA45件の研究
- Philadelphia, PA44件の研究
- Baltimore, MD43件の研究
- Nashville, TN43件の研究
- Seattle, WA42件の研究
- Washington, DC38件の研究
Salt Lake Cityにおける他の研究
- 非小細胞肺癌31件の研究
- がん（全種類）27件の研究
- 乳がん27件の研究
- 大腸癌22件の研究
- 肺がん21件の研究
- 悪性黒色腫21件の研究
- 多発性骨髄腫21件の研究
- 転移性癌20件の研究
- 卵巣がん19件の研究
- 肥満症18件の研究
- 急性骨髄性白血病17件の研究
- 心不全17件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。